Mitsubishi Tanabe to pay $1.1bn for Parkinson's drug formulator Neuroderm

By Gareth Macdonald

- Last updated on GMT


Related tags Pharmacology Parkinson

Mitsubishi Tanabe Pharma has agreed to pay $1.1bn (€943m) to acquire Parkinson’s disease focused formulation and drug-device developer Neuroderm Ltd.

Neuroderm’s lead product candidate – ND0612 – is a liquid formulation combining levodopa and carbidopa. The production – which is in Phase III trials in the US - is designed for continuous administration using specially developed, belt worn pump.

The Israel-based firm has a second Parkinson’s disease drug ND0701 (apomorphine) in development, as well as a transdermal CNS disease medication called ND0801 (nicotide and opipramol).

Related news

Related products

Spray Dried Powders for High Dose Drug Delivery

Spray Dried Powders for High Dose Drug Delivery

Catalent | 01-Feb-2022 | Product Presentation

This Catalent webinar will explore how spray dried particles provide an attractive, carrier-free option for highly dispersed delivery of API to deep lung...

Related suppliers

Follow us


View more